A clinician-led peptide therapy business typically requires $45,000–$125,000 in startup cash and $12,000–$45,000 per month before medication fulfillment. A more complex multi-state launch can exceed $125,000–$300,000 upfront and $35,000–$100,000 monthly. These are planning ranges, not official fee schedules; clinician compensation, state licensing, legal structure, insurance, acquisition, technology, and the pharmacy model drive the result.
What is included in a peptide clinic startup cost?
A realistic budget includes more than a website and a prescribing clinician. The business may need a compliant entity structure, licensed clinicians, state-by-state credentialing, malpractice coverage, telehealth technology, laboratory workflows, pharmacy contracts, patient support, advertising review, payment operations, and working capital.
The first major decision is whether the company will evaluate patients and send prescriptions to a licensed pharmacy or operate a dispensing, pharmacy, or outsourcing-facility model. The latter can add facility, licensing, quality-system, personnel, inventory, storage, shipping, and regulatory expenses. FDA states that compounded drugs are not FDA-approved and that compounding operates under different federal frameworks, including sections 503A and 503B.
The figures below assume a telehealth-first business that uses an external licensed pharmacy, outsources most laboratory services, and does not own a pharmacy or outsourcing facility.
How much does it cost to start a peptide therapy business?
For a lean launch, plan on $45,000–$125,000 upfront. A standard launch across several states may require $75,000–$150,000, while a multi-state growth platform may reach $150,000–$300,000 or more.
| Startup category | Lean launch | More robust launch | What changes the cost |
|---|---|---|---|
| Entity formation, contracts, and healthcare counsel | $8,000–$25,000 | $25,000–$60,000+ | Professional-entity and MSO structure, clinician agreements, pharmacy and lab contracts, privacy terms, and advertising review |
| State licensing and credentialing | $2,000–$15,000 | $15,000–$50,000+ | Number of states and clinicians, applications, registrations, and credentialing requirements |
| Medical director or prescribing-clinician onboarding | $5,000–$20,000 | $20,000–$50,000+ | Recruiting, policy development, chart-review processes, onboarding, and initial compensation |
| Malpractice, general liability, and cyber insurance | $5,000–$20,000 | $20,000–$50,000+ | Geography, specialty, prescribing model, patient volume, and compounded products |
| Telehealth, EHR, scheduling, forms, and messaging | $3,000–$15,000 | $15,000–$40,000+ | Implementation, integrations, security controls, and patient volume |
| Website, branding, copy, and education | $5,000–$20,000 | $20,000–$60,000 | Custom design, content volume, review, and conversion testing |
| Billing, payments, accounting, and compliance systems | $2,000–$10,000 | $10,000–$30,000 | Merchant setup, chargebacks, bookkeeping, tax support, monitoring, and records retention |
| Laboratory setup and clinical supplies | $2,000–$10,000 | $10,000–$30,000 | External lab network versus in-house collection and program scope |
| Initial marketing and patient acquisition | $10,000–$40,000 | $40,000–$150,000+ | Content, paid media, creative, call handling, and testing |
| Working-capital reserve | $15,000–$50,000 | $50,000–$150,000+ | Fixed expenses and the planned three-to-six-month reserve |
| Estimated total | $45,000–$125,000 | $125,000–$300,000+ | Excludes unusually high facility, payroll, inventory, or acquisition costs |
These figures are planning estimates. They do not predict revenue, margins, patient volume, return on investment, or profitability.
What are the recurring costs in a peptide therapy business budget?
A lean business may spend $12,000–$45,000 per month before medication fulfillment. A multi-state operation with several clinical teams and a larger acquisition program can exceed $100,000 per month.
| Monthly expense | Planning range | Primary cost driver |
|---|---|---|
| Clinician compensation | $5,000–$25,000+ | Visit volume, asynchronous work, chart review, follow-up, and employment or contractor structure |
| Medical director or clinical oversight | $2,000–$10,000+ | State structure, quality review, patient volume, and scope of duties |
| Patient support and operations | $2,000–$15,000+ | Scheduling, messaging, refill requests, support, and administrative workload |
| Telehealth, EHR, CRM, phone, and e-prescribing | $500–$5,000+ | Vendor stack, integrations, and patient volume |
| Laboratory services | $1,000–$15,000+ | Whether testing is bundled, separately paid, or absorbed by the practice |
| Insurance | $500–$4,000+ | Coverage limits and risk profile |
| Legal, compliance, and accounting | $1,000–$8,000+ | Multi-state footprint, audits, contracts, and advertising review |
| Marketing and advertising | $5,000–$50,000+ | Acquisition strategy and testing budget |
| Payment processing and refunds | 2%–5% of collections, planning estimate | Card mix, subscriptions, refunds, and chargebacks |
| Patient education and clinical content | $500–$5,000 | Internal production versus outside support |
Medication fulfillment should be modeled separately as a variable cost per active patient, not as a fixed startup expense. The financial model should specify who pays the pharmacy, who handles delivery problems, how refunds work, whether the practice receives pharmacy-related compensation, and who manages medication complaints or adverse-event communications.
For recurring memberships, include clear disclosure of material terms, express consent before charging, and a simple cancellation method. The FTC’s 2024 amendments to its Negative Option Rule are not currently in force after the U.S. Court of Appeals for the Eighth Circuit vacated them on July 8, 2025. The FTC’s March 11, 2026 advance notice of proposed rulemaking is only a proposal. The Restore Online Shoppers’ Confidence Act still provides relevant requirements for recurring online plans.
Which costs vary most by state and program?
The largest state-driven variables are clinician licensing, professional-entity structure, physician ownership or control requirements, supervision, delegation, telehealth standards, and requirements for an initial evaluation. These rules vary by state, so a national budget should include a state-by-state legal and credentialing workstream rather than one national license line.
- California: The Medical Board states that corporations and artificial entities do not have professional rights, privileges, or powers under Business and Professions Code section 2400. It identifies clinical hiring, medical records, coding and billing decisions, equipment and supplies, and treatment decisions as areas that should remain under physician control. A physician treating a patient located in California must hold a California license.
- Texas: Texas materials emphasize physician control of medical decisions and medical policies and require attention to supervision of non-physicians providing telemedicine services. Budget for Texas-specific policies, delegation documentation, physician oversight, and legal review of clinician agreements.
- Florida: Florida materials state that prescribing based only on an electronic questionnaire does not meet the required standard of care. The evaluation must include a documented history and physical examination sufficient to establish the diagnosis, discussion of treatment options and risks and benefits, and contemporaneous records.
- Massachusetts: Massachusetts does not issue a special telemedicine license; a physician must obtain a full license. When controlled substances are involved, applicable DEA registration and Massachusetts controlled-substance registration requirements also apply.
- New York: New York guidance addresses restrictions on unauthorized corporate practice of medicine and identifies professional corporations, professional limited-liability entities, licensed providers, and certain authorized entities as possible structures. A founder should not assume that a standard investor-owned LLC is sufficient.
These are examples, not a complete 50-state survey. A program involving laboratory interpretation, follow-up monitoring, compounded products, or controlled substances may require different clinical, pharmacy, documentation, and insurance assumptions.
How do FDA and pharmacy rules affect the budget?
FDA states that compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing. FDA recommends that compounding be used when a patient’s needs cannot be met by an FDA-approved drug and that prescriptions be obtained through state-licensed pharmacies.
Budget for:
- 1Pharmacy due diligence and contracting.
- 2Documentation of clinical rationale and prescribing workflow.
- 3Patient-specific prescription processes where required.
- 4Adverse-event and medication-complaint procedures.
- 5Review of pharmacy communications and fulfillment responsibilities.
- 6Legal review of product descriptions and advertising.
- 7A contingency plan if FDA changes shortage, bulk-substance, or compounding policy.
GLP-1 compounding status can change. FDA’s April 2026 update addressed restrictions involving products that are essentially copies of commercially available drugs. FDA’s April 30, 2026 announcement proposed excluding certain GLP-1 substances from the 503B bulks list; that announcement was a proposal, not a final determination. A business should not treat a compounded product line as permanently available.
FDA has also identified safety concerns for multiple bulk substances nominated for compounding, including concerns involving immunogenicity, impurities, limited human safety information, and inadequate characterization. Product selection belongs in a clinician-led and regulatory-reviewed process; supplier advertising alone is not a legality determination.
What does telehealth technology add to the peptide clinic startup cost?
A compliant technology stack generally includes telehealth visits, an EHR, scheduling, intake and consent forms, secure messaging, e-prescribing where appropriate, payment tools, staff access controls, and records retention. HHS recommends evaluating privacy safeguards, contracts, EHR integration, consent functionality, patient access, and whether vendors charge per visit or a fixed fee.
MDLaunchr is one infrastructure option for a branded, clinician-led telehealth operation. It supports white-label programs under a business’s brand while independently licensed clinicians make clinical decisions. It is not a pharmacy, regulator, law firm, or substitute for state-specific legal and clinical review. When comparing a custom build with a white-label model, examine implementation fees, recurring platform costs, data access, pharmacy workflow, state coverage, clinician contracting, support boundaries, and what remains the founder’s responsibility.
How should a founder model three launch scenarios?
Use a scenario model instead of one optimistic total:
Lean pilot
Assume one clinician or a small clinical team, one or two states, an external licensed pharmacy, outsourced labs, limited paid advertising, and a small support function. Planning target: $45,000–$75,000 upfront and $12,000–$25,000 monthly.
Standard clinician-led practice
Assume three to five states, a medical director plus additional clinicians, patient support, a structured laboratory program, paid acquisition, content production, and formal quality review. Planning target: $75,000–$150,000 upfront and $25,000–$60,000 monthly.
Multi-state growth platform
Assume ten or more states, multiple clinical teams, centralized support, membership billing, integrations, compliance personnel, and a larger marketing operation. Planning target: $150,000–$300,000 or more upfront and $50,000–$100,000 monthly, before variable medication expense.
Startup budget checklist
Before committing funds, confirm that the model answers each question:
- Which specific products will clinicians offer, and are they FDA-approved, compounded, or investigational?
- Will the business prescribe only, or dispense, package, store, or ship medication?
- Which entity will employ or contract with clinicians?
- Which states will be served at launch, and what licenses or registrations are required?
- Does each state allow the proposed ownership and management structure?
- What evaluation, consent, documentation, supervision, and follow-up workflows apply?
- Which pharmacies, laboratories, and vendors will sign appropriate privacy agreements?
- What claims will appear in ads, testimonials, provider biographies, and patient education?
- What happens if FDA changes a shortage, bulk-list, or compounding policy?
- Will customers pay a membership fee, visit fee, medication fee, or bundled price?
- Who manages delivery failures, refunds, medication complaints, and product discontinuation?
- Is the reserve sufficient for at least three to six months of fixed expenses?
A healthcare attorney, qualified clinician, and relevant licensing-board materials should review the proposed structure, clinical workflow, and program claims before launch. This is a planning article, not legal or medical advice.
For founders comparing infrastructure options, review MDLaunchr pricing for a branded telehealth program and compare the included infrastructure with the costs you would otherwise assemble independently. The useful comparison is total operating responsibility, not only the platform line on a spreadsheet.
Related reading: Med Spa Weight Loss Advertising Rules: FTC and FDA (2026), How Long Does It Take to Launch a GLP-1 Telehealth Program?.
Written and reviewed by MDLaunchr's clinical and compliance team. We build white-label telehealth infrastructure for founders, creators, and healthcare operators—covering providers, pharmacy, technology, and compliance.
This article is for general informational and educational purposes only and is not medical, legal, or regulatory advice. It does not create a provider-patient relationship and should not be used to diagnose or treat any condition. Telehealth and compounding regulations vary by state and change over time—consult qualified legal, clinical, and compliance professionals before launching or operating a telehealth program.
Frequently asked questions
How much money do I need to open a peptide clinic?
A lean telehealth-first peptide clinic should be modeled at approximately $45,000–$125,000 upfront, with more required for multiple states, additional clinicians, dispensing operations, or a larger marketing launch.
What is the monthly cost of running a peptide therapy business?
Monthly operating expenses commonly fall in the $12,000–$45,000 range before medication fulfillment, while multi-state operations may exceed $100,000 monthly.
What is the largest expense in a peptide clinic startup budget?
Clinician compensation, marketing, working capital, legal and entity structuring, insurance, and state licensing are often the largest categories; the leading variable depends on the launch model.
Does the budget include the cost of medication?
The ranges separate medication from fixed startup and operating costs because fulfillment is generally a variable cost per active patient and depends on the pharmacy and product model.
Can a non-doctor own a peptide therapy business?
Ownership and control rules vary by state, and some states restrict how non-clinical entities can control professional services.
Do I need a medical director for a peptide clinic?
The need for a medical director, clinical oversight, supervision, or delegation arrangement depends on the state, clinician mix, entity structure, and scope of services.
How much does peptide clinic software cost?
Planning ranges are $3,000–$15,000 for implementation and $500–$5,000 or more per month for telehealth, EHR, CRM, phone, and e-prescribing tools.
Are compounded peptides FDA-approved?
No. FDA states that compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.
Can a peptide clinic use a questionnaire-only intake?
A questionnaire alone may not satisfy a state’s clinical standard; Florida materials specifically state that prescribing based solely on an electronic questionnaire is insufficient.
Should medication fulfillment be handled by the clinic?
That is a business and regulatory design decision, because prescribing through an external licensed pharmacy creates a different cost structure from dispensing or shipping medication directly.
How much working capital should a new peptide clinic keep?
The planning memo recommends reserving at least three to six months of fixed operating expenses.
Is a peptide therapy business guaranteed to be profitable?
No. Startup ranges cannot predict revenue, margins, patient volume, or profitability.